Triple Regulator TIA-39-C20

Triple Regulator TIA-39-C20 is identified in this catalogue as Retatrutide.

Retatrutide is a triple hormone receptor agonist activating three metabolic pathways at once: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon.

It is studied for helping regulate appetite, fullness, blood sugar, insulin response, digestion speed, fat metabolism, and energy expenditure. Semaglutide works through GLP-1; Tirzepatide through GIP + GLP-1; Retatrutide adds glucagon as a third receptor.

In practical terms it is researched for reduced appetite, increased fullness, less food noise, slower gastric emptying, better blood sugar control, improved insulin response, greater weight-loss potential, waist-size reduction, fat-mass reduction, energy-expenditure signaling, and obesity-related metabolic improvement.

Retatrutide is not a stimulant, thermogenic, or old-school fat burner. It works through hormone signaling. The GLP-1 side regulates appetite/digestion/insulin/glucose; the GIP side supports incretin signaling; the glucagon side is studied for energy expenditure and liver/fat metabolism. It should not be described as a casual weight-loss shortcut.

Retatrutide (LY3437943) is a synthetic peptide and triple hormone receptor agonist designed to activate the GIP receptor, GLP-1 receptor, and glucagon receptor.

GLP-1 activation supports glucose-dependent insulin secretion, suppresses glucagon when glucose is elevated, slows gastric emptying, reduces appetite, and supports fullness signaling.

GIP activation supports glucose-dependent insulin secretion and may influence adipose tissue metabolism, body-weight regulation, and broader incretin signaling when combined with GLP-1 activity.

Glucagon receptor activation is the third piece, traditionally known for raising blood glucose, but also linked to energy expenditure, lipid metabolism, hepatic metabolism, and fat oxidation. Retatrutide combines appetite control and glucose regulation with a stronger energy-expenditure and metabolic effect.

Within Metabolic / Weight Loss, Retatrutide sits on the advanced incretin / multi-receptor metabolic regulation side of the category, not a mitochondrial peptide, stimulant, or fat-cell enzyme inhibitor. It is a multi-pathway endocrine compound studied for appetite, glucose, insulin, digestion, body weight, and energy metabolism.

Retatrutide has strong emerging human clinical evidence but remains investigational and is not FDA-approved.

In an NEJM phase 2 trial in adults with obesity, Retatrutide produced a 24.2% mean weight reduction at the 12 mg dose over 48 weeks, with weight loss still ongoing at trial end. A Lancet phase 2 T2D trial showed clinically meaningful glycemic improvement and robust weight reduction over 36 weeks. A Nature Medicine phase 2 study evaluated Retatrutide in MASLD (metabolic dysfunction-associated steatotic liver disease).

As of June 2026, Lilly has reported phase 3 data (TRIUMPH-1, TRANSCEND-T2D-1) describing substantial weight reduction, A1C improvement, and improvements in obesity-related conditions including obstructive sleep apnea and knee osteoarthritis pain.

Strongest themes: triple incretin receptor activation, appetite regulation, fullness signaling, reduced food intake, slower gastric emptying, blood sugar control, glucose-dependent insulin secretion, body-weight reduction, waist circumference reduction, fat-mass reduction, energy-expenditure signaling, T2D research, obesity-related metabolic dysfunction, liver-fat/MASLD research, OSA research in obesity, knee osteoarthritis pain research in obesity. The molecule has serious clinical promise, but catalogue products labeled Retatrutide should not be described as FDA-approved medication.

Most common adverse effects in clinical research are gastrointestinal: nausea, vomiting, diarrhea, constipation, reduced appetite, abdominal discomfort, and indigestion, common across incretin-based therapies, especially during dose escalation.

Potential concerns include severe GI reactions, dehydration from vomiting/diarrhea, gallbladder issues, pancreatitis risk considerations, hypoglycemia (especially with insulin or secretagogues), changes in heart rate, excessive weight loss, lean-mass loss risk without proper nutrition and resistance training, malnutrition risk with aggressive appetite suppression, and unknown long-term safety while investigational.

Because Retatrutide includes glucagon receptor activity, it may have different metabolic effects than GLP-1-only or GIP/GLP-1 compounds, part of what makes it powerful and why long-term safety data matters.

FDA states Retatrutide and cagrilintide cannot be used in compounding under federal law, are not components of FDA-approved drugs, and have not been found safe and effective for any condition. Retatrutide should not be marketed as an FDA-approved weight-loss drug, diabetes drug, obesity medication, compounded medication, or wellness therapy.

For tested athletes, Retatrutide presents serious anti-doping risk. Because it is investigational and not approved for human therapeutic use by a government regulatory authority, it may fall under WADA's S0 Non-Approved Substances category, athletes should not assume it is allowed just because GLP-1 medications as a class are being monitored rather than universally banned.

Triple Regulator TIA-39-C20, identified as Retatrutide, is an investigational triple GIP, GLP-1, and glucagon receptor agonist studied for appetite regulation, fullness signaling, glucose control, insulin response, slowed gastric emptying, body-weight reduction, fat-mass reduction, energy-expenditure signaling, type 2 diabetes research, obesity research, liver-fat research, and obesity-related metabolic complications.

Triple Regulator TIA-39-C20 is best positioned as a Retatrutide-based metabolic research compound involved in triple hormone receptor signaling.

Its strongest practical relevance is the study of how GIP, GLP-1, and glucagon receptor activation may regulate appetite, blood sugar, insulin response, digestion speed, body weight, fat mass, energy expenditure, and broader metabolic health.

The most accurate framing is advanced metabolic and weight-management research, not a casual fat burner, stimulant, guaranteed weight-loss shortcut, bodybuilding compound, anti-aging therapy, compounded medication, or FDA-approved obesity treatment.